Achievement of No-to-minimal Itch and Sleep Improvement with Tapinarof Cream 1% Once Daily in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age with Atopic Dermatitis
Simpson E, Siri D, Chovatiya R, Shahriari M, Burnette A, Craiglow B, Brown P, Tallman A. Achievement of No-to-minimal Itch and Sleep Improvement with Tapinarof Cream 1% Once Daily in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age with Atopic Dermatitis. SKIN The Journal Of Cutaneous Medicine 2024, 8: s459. DOI: 10.25251/skin.8.supp.459.Peer-Reviewed Original ResearchPP-NRSPatient Oriented Eczema MeasurePhase 3 trialAtopic dermatitisWeek 8Eczema Area and Severity Index scorePeak Pruritus Numerical Rating ScaleBody surface area involvementPruritus Numerical Rating ScaleInvestigator's Global AssessmentNumerical rating scaleSurface area involvementSeverity index scoreSleep disturbanceAnalyzed post hocSleep improvementImprovement of sleepTapinarof creamEvaluate sleep disturbancesSuperior efficacySleep disturbance scoresArea involvementTapinarofItchingGlobal assessment